Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 250Session 2025-2026

Enacting the right to try for individualized treatments act to permit a manufacturer to make an individualized investigative treatment available to a requesting patient.

As Introduced

Skip to main content Kansas Legislature kslegislature.gov menu Home House account_balanceAbout the House groupsRepresentatives campaignEvents chairSeating Chart auto_storiesJournals & Calendars manage_accountsChief Clerk of the House gavelRules Senate account_balanceAbout the Senate groupsSenators campaignEvents assignment_indAppointments chairSeating Chart auto_storiesJournals & Calendars manage_accountsSecretary of the Senate gavelRules Committees groupsCommittees eventHearing Schedule handshakeConference Committee Schedule Measures & Laws gavelAll Measures account_balanceHouse Measures account_balanceSenate Measures account_balanceVotes topicSubject Index summarizeReports menu_bookStatutes schoolHow a Bill Becomes Law menu_bookLegislative Procedure Manual Today campaignLive Floor Activity videocamHouse Video videocamSenate Video live_tvStatehouse Live & Archive smart_displayYouTube Channel Resources Archive Search description Go to bill or resolution arrow_forward A− A+ search Search bills, resolutions, and statutes help

Keywords
Enter any words to search bills, statutes, and documents.
water quality funding

Bill or Resolution Number
Type a number and press Enter to go directly to the detail page.
HB 2590 SCR 1611

Statute Number
68-102 72-3715

Exact Phrase
Wrap your query in quotes.
“rules of evidence”

Document Type
Prefix with a type to narrow results.
testimony: HB 2513 minutes: budget

    Searching…

    No results found.

    search Search bills, resolutions, and statutes Home House About the House Representatives Events Seating Chart Journals & Calendars Chief Clerk of the House Rules Senate About the Senate Senators Events Appointments Seating Chart Journals & Calendars Secretary of the Senate Rules Committees All Committees Hearing Schedule Conference Committee Schedule Measures & Laws All Measures House Measures Senate Measures Votes Subject Index Reports Statutes How a Bill Becomes Law Legislative Procedure Manual Resources Today Live Floor Activity House Video Senate Video Statehouse Live & Archive YouTube Channel Archive Search
    1. SB 250›
    2. SB 250 — As Introduced

    Kansas Legislature

    SB 250 — As Introduced

    picture_as_pdf Download PDF Session of 2025SENATE BILL No. 250By Committee on Public Health and Welfare2-71AN ACT concerning health and healthcare; relating to treatments for life-2threatening illnesses; enacting the right to try for individualized 3treatments act to permit certain manufacturers to make individualized 4investigative treatments available to eligible requesting patients.56Be it enacted by the Legislature of the State of Kansas:7Section 1. (a) As used in this act, unless the context otherwise 8requires:9(1) "Eligible patient" means an individual who has:10(A) A life-threatening or severely debilitating illness, attested to by 11the patient's treating physician;12(B) considered all other treatment options currently approved by the 13United States food and drug administration;14(C) received a recommendation from the patient's physician for an 15individualized investigational treatment, based on analysis of the patient's 16genomic sequence, human chromosomes, deoxyribonucleic acid, 17ribonucleic acid, genes, gene products, such as enzymes and other types of 18proteins, or metabolites;19(D) given written, informed consent for the use of the investigational 20drug, biological product or device; and21(E) documentation from the patient's physician that such patient 22meets the requirements of this act.23(2) "Individualized investigational treatment" means drugs, biological 24products or devices that are unique to and produced exclusively for use on 25an individual patient, based on the patient's own genetic profile. 26"Individualized investigational treatment" includes, but is not limited to, 27individualized gene therapy antisense oligonucleotides (ASO) and 28individualized neoantigen vaccines.29(3) "Life-threatening or severely debilitating illness" means the same 30as currently defined in 21 C.F.R. § 312.81.31(4) "Physician" means an individual licensed by the state board of 32healing arts to practice medicine and surgery. 33(5) "Written, informed consent" means a written document that is 34signed by the patient, a parent if the patient is a minor, the legal guardian 35or authorized representative as defined in K.S.A. 65-6836, and 36amendments thereto, and attested to by the patient's physician and a 1witness, that includes all of the following:2(A) An explanation of the currently approved products and treatments 3for the disease or condition from which the patient suffers;4(B) an attestation that the patient concurs with such patient's 5physician that all currently approved and conventionally recognized 6treatments are unlikely to prolong the patient's life;7(C) clear identification of the specific proposed individualized 8investigational drug, biological product or device that the patient is 9seeking to use;10(D) a description of the potentially best and worst outcomes of using 11the individualized investigational drug, biological product or device and a 12realistic description of the most likely outcome. The description shall 13include the possibility that new, unanticipated, different or worse 14symptoms might result and that death could be hastened by the proposed 15treatment. Such description shall be based on the physician's knowledge of 16the proposed treatment in conjunction with an awareness of the patient's 17condition;18(E) a statement that the patient's health plan or third party 19administrator and provider are not obligated to pay for any care or 20treatments as a result of the use of the individualized investigational drug, 21biological product or device, unless such provider is specifically required 22to do so by law or contract;23(F) a statement that the patient's eligibility for hospice care may be 24withdrawn if the patient begins curative treatment with the individualized 25investigational drug, biological product or device and that such care may 26be reinstated if such treatment ends and the patient meets hospice 27eligibility requirements; and28(G) a statement that the patient understands that such patient is liable 29for all expenses related to the use of the individualized investigational 30drug, biological product or device and that this liability extends to the 31patient's estate, unless a contract between the patient and the manufacturer 32of the drug, biological product or device states otherwise.33(6) "Eligible facility" means an institution that is operating under a 34federalwide assurance for the protection of human subjects under 42 35U.S.C. § 289(a) and 45 C.F.R. part 46 and the "eligible facility" is subject 36to the federalwide assurance laws, regulations, policies and guidelines 37including renewals or updates.38(b) (1) A manufacturer operating within an eligible facility, pursuant 39to all applicable federalwide assurance laws and regulations, may make 40available an individualized investigative treatment and an eligible patient 41may request an individualized investigational drug, biological product or 42device from an eligible facility or manufacturer operating within an 43eligible facility under this act. This act does not require that a 1manufacturer make available an individualized investigational drug, 2biological product or device to an eligible patient.3(2) An eligible facility or manufacturer operating within an eligible 4facility may:5(A) Provide an individualized investigational drug, biological product 6or device to an eligible patient without receiving compensation; or7(B) require an eligible patient to pay the costs of, or the costs 8associated with, the manufacture of the investigational drug, biological 9product or device.10(c) This act shall not expand the coverage required of an insurer 11under the insurance code of the state of Kansas.12(d) A health plan, third party administrator or governmental agency 13may provide coverage for the cost of an individualized investigational 14drug, biological product or device or the cost of services related to the use 15of an individualized investigational drug, biological product or device 16under this act, except that, this act shall not require:17(1) Any governmental agency to pay costs associated with the use, 18care or treatment of a patient with an individualized investigational drug, 19biological product or device; or20(2)  a hospital or facility licensed under article 4 of chapter 65 of the 21Kansas Statutes Annotated, and amendments thereto, to provide new or 22additional services unless approved by the hospital or facility.23(e) If a patient dies while being treated by an individualized 24investigational drug, biological product or device, the patient's heirs shall 25not be liable for any outstanding debt related to the treatment or lack of 26insurance due to the treatment.27(f) (1) A licensing board shall not revoke, fail to renew, suspend or 28take any discplinary action against a healthcare provider's license issued 29under chapter 65 of the Kansas Statutes Annotated, and amendments 30thereto, based solely on the healthcare provider's recommendations to an 31eligible patient regarding access to or treatment with an individualized 32investigational drug, biological product or device.33(2) Counseling, advice or a recommendation consistent with medical 34standards of care from a licensed healthcare provider shall not be a 35violation of this act.36(g) An entity responsible for medicare certification shall not take 37action against a healthcare provider's medicare certification based solely 38on the healthcare provider's recommendation that a patient have access to 39an individualized investigational drug, biological product or device.40(h) An official, employee, or agent of this state shall not block or 41attempt to block an eligible patient's access to an individualized 42investigational drug, biological product or device.43(i) This act shall not create a private cause of action against a 1manufacturer of an individualized investigational drug, biological product 2or device or against any other person or entity involved in the care of an 3eligible patient using the individualized investigational drug, biological 4product or device for any harm done to the eligible patient resulting from 5the individualized investigational drug, biological product or device if the 6manufacturer or other person or entity is complying in good faith with the 7terms of this act and has exercised reasonable care.8(j) This act shall not affect any mandatory healthcare coverage for 9participation in clinical trials under the insurance code of the state of 10Kansas.11(k) This section shall be known and may be cited as the right to try 12for individualized treatments act.13Sec. 2. This act shall take effect and be in force from and after its 14publication in the statute book. search keyboard_arrow_up keyboard_arrow_down Page 1 Page 2 Page 3 Page 4 arrow_upward Top Kansas State Legislature

    300 SW 10th Ave, Topeka, KS 66612

    Ad Astra Per Aspera

    Kansas Legislative Hotline
    In-State: 1-800-432-3924
    Out-of-State: 785-296-2149

    Government

    • Legislators
    • House
    • Representatives
    • Senate
    • Senators
    • Committees

    Resources

    • Bills & Measures
    • Today
    • Live
    • Journals
    • Calendars
    • Archived Records
    • Laws
    • Search
    • RSS Feeds

    Support

    • Contact Us
    • Accessibility
    • Privacy Policy
    • Visit Us
    © 2026 Kansas State Legislature. All rights reserved. Data updated 0 minutes ago · 3:52 PM 11/14/2026

    Official text from the Kansas Legislature. Formatting has been adapted for reading on Ratifi.